Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06834165 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
A Phase 4 study of Allergic Reactions, sponsored by ARS Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 600
- Enrollment target
- 2
- Study locations
NCT06834165 is a Phase 4 study of Allergic Reactions that is actively recruiting participants, run by ARS Pharmaceuticals. The registered enrollment target is 600 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06834165, a Phase 4 study of Allergic Reactions, is actively recruiting participants, sponsored by ARS Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 600 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.
Conditions Studied
Interventions
- DRUG Neffy
- DRUG Adrenaline
Study Locations (2)
California
- Orso Health, Inc. - La Jolla
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06834165
The ClinicalTrials.gov registry entry for NCT06834165 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ARS Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Reactions appearing as the primary indexed condition, and to 2 interventions - of which Neffy is the first listed.
NCT06834165 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Ohio.
Frequently Asked Questions
What is clinical trial NCT06834165 about?
NCT06834165 is a clinical study titled "Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy". The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.
What is the current status of trial NCT06834165?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2025-05-20. Estimated completion is 2026-06.
What conditions does trial NCT06834165 study?
This clinical trial studies the following conditions: Allergic Reactions.
What interventions are being tested in trial NCT06834165?
The interventions under investigation include: Neffy (DRUG), Adrenaline (DRUG).
Who is sponsoring clinical trial NCT06834165?
This trial is sponsored by ARS Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06834165 being conducted?
This trial has 2 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Reactions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.